tbuckley/cabot-search huggingface dataset:
The effect and safety of Clino-san on vaginal symptoms in breast cancer survivors: A randomized, controlled study
Authors: J. Kim, Y. Lee, N. Park, Y. Song, S. Kang
Journal: Journal of Clinical Oncology (2009)

e20525 Background: The purpose of this study was to determine the effect of Clino-san on vaginal symptoms and atrophy in breast cancer survivors treated with chemotherapy or endocrine therapy. Methods: A randomized, double-blind, placebo-controlled study. Breast cancer survivors who experienced menopause after chemotherapy or endocrine therapy were enrolled voluntarily and randomly applied vaginal topical lactic acid, Clino-san or placebo three times per week for 12 weeks. Vaginal dryness and dyspareunia measured by visual analogue scale, vaginal health index, vaginal pH, and the effect on endometrium or ovary were evaluated. Results: Among 89 enrolled women, 81 were evaluated. Forty-two received Clino-san treatment, and the remaining 39 received placebo. Vaginal dryness and dyspareunia in Clino-san treatment group improved compared with placebo group (p=0.012). Clino-san increased vaginal health index, however it is not statistically significant (p=0.058). Vaginal pH decreased more in Clino-san treatment group (p=0.025). There was no significant difference of adverse effects between two groups other than mild irritation at the early time of Clino-san use. Conclusions: Vaginal topical Clino-san could relieve the vaginal symptoms and improve the vaginal health in breast cancer survivors who experienced menopause after cancer treatment. No significant financial relationships to disclose.
The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MO AIC, a multicenter cluster-randomized phase III study (SAKK 95/06)
Authors: F. Strasser, D. Blum, R. von Moos, R. Cathomas, K. Ribi, S. Aebi, D. Betticher, S. Hayoz, D. Klingbiel, P. Brauchli, M. Haefner, S. Mauri, S. Kaasa, D. Koeberle
Journal: Annals of Oncology (2015)
Enhancement of Carcinogenesis by Prostaglandins in Male Albino Swiss Mice2
Authors: A. Lupulescu
Journal: JNCI Journal of the National Cancer Institute (1978)

The effects of prostaglandin E2 (PGE2) and prostaglandin F2α (PGF2α) on the development of skin tumors were studied in male albino Swiss mice treated with a carcinogen. The formation of squamous cell carcinoma was markedly enhanced by concomitant PGE2 and PGF2α administration to mice treated with 3-methylcholanthrene (MCA) for 2 months, whereas only epidermal hyperplasia occurred in mice treated with MCA alone for 2 months. Radioisotope studies showed an increase in incorporation of [3H]thymidine, followed by [3H]uridine, [3H]proline, and [3H]leucine in the neoplastic cells of mice treated with MCA and prostaglandin as compared to the incorporation seen in mice treated with MCA alone, prostaglandin alone, or in control mice. Light and electron microscopic autoradiography revealed a significant increase in labeled cells and grain distribution of [3H]thymidine over nuclei, [3H]uridine over nucleoli, and [3H]leucine over the cytoplasm of neoplastic cells compared to the increase in distribution observed in hyperplastic or control epidermal cells. Electron microscopy showed the predominance of neoplastic squamous cells with large nuclei, an increased nuclearcytoplasmic ratio, dark and light cells with distinct ultrastructural features, increased polysome and dense granule populations, altered mitochondria, and discontinuities of the basement membrane in mice treated with MCA and PGF2α or MCA and PGE2. Hyperplastic and dysplastic cellular changes only appeared in the epidermis of MCA-treated mice. A moderate increase in polysomes, tonofilaments, and enlarged nuclei and intercellular spaces occurred in prostaglandin-treated mice. These findings demonstrate that prostaglandins are important as cocarcinogens for cutaneous carcinogenesis.
Inferring Very Recent Population Growth Rate from Population-Scale Sequencing Data: Using a Large-Sample Coalescent Estimator
Authors: Hua Chen, Jody Hey, Kun Chen
Journal: Molecular Biology and Evolution (2015)

Large-sample or population-level sequencing data provide unprecedented opportunities for inferring detailed population histories, especially recent demographic histories. On the other hand, it challenges most existing population genetic methods: Simulation-based approaches require intensive computation, and analytical approaches are often numerically intractable when the sample size is large. We propose a computationally efficient method for simultaneous estimation of population size, the rate, and onset time of population growth in the very recent history, using the pattern of the total number of segregating sites as a function of sample size. Coalescent simulation shows that it can accurately and efficiently estimate the parameters of recent population growth from large-scale data. This approach has the flexibility to model population history with multiple growth stages or other epochs, and it is robust when the sample size is very large or at the population scale, for which the Kingman's coalescent assumption is not valid. This approach is applied to recently published data and estimates the recent population growth rate in the European population to be 1.49% with the onset time 7.26 ka, and the rate in the African population to be 0.735% with the onset time 10.01 ka.
Reciprocal translocation involving the short arms of chromosomes 7 and 11, t(7p-;11p+), associated with myeloid leukemia with maturation
Authors: Y Sato, S Abe, K Mise, M Sasaki, N Kamada, K Kouda, M Musashi, Y Saburi, A Horikoshi, Y Minami
Journal: Blood (1987)
Implementing Recommendations for Depression Screening of Adults
Authors: Helen S. Mayberg
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Long-term survival of patients with localized diffuse histiocytic lymphoma.
Authors: E E Vokes, J E Ultmann, H M Golomb, E R Gaynor, D J Ferguson, M L Griem, D Oleske
Journal: Journal of Clinical Oncology (1985)

From January 1970 to March 1981, localized diffuse histiocytic lymphoma (DHL) was identified in 31 patients by exploratory laparotomy and splenectomy (pathologic stage I, 17 patients; pathologic stage II, 14 patients) at the University of Chicago. The median follow-up time was 72 months. All patients were previously untreated and received radiation therapy as their primary treatment modality. Chemotherapy was administered only at the time of relapse. All but two patients achieved a complete remission (CR) with radiation therapy. The actuarial disease-free survival for patients with stage I disease is 94% at 5 years and 72% at 10 years. For stage II disease, the disease-free survival is 56% at 5 years and 31% at 10 years. The difference in the disease-free survival between stage I and II is statistically significant (P = .02). The survival at 10 years is 70% for stage I disease and 46% for stage II disease. Five patients had documented relapses (four had stage II disease). Only two of those who relapsed achieved a second CR with salvage chemotherapy. Our data show an excellent outcome in patients with pathologic stage I disease, indicating that a high percentage of these cases can be cured with radiotherapy alone. Patients with clinical stage II disease might be served better with chemotherapy.
Making Precision Medicine Socially Precise. Take a Deep Breath
Authors: Sam S. Oh, Marquitta J. White, Christopher R. Gignoux, Esteban G. Burchard
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

trigger epigenetically modifies asthma susceptibility genes, making this individual more prone to asthma development.In addition, identifying the epigenetic modifications resulting from coexposure of AECs to IL-13 combined with other stimuli such as cigarette smoke will be of importance, as aberrant DNA methylation has been detected in small airways of patients with chronic obstructive pulmonary disease (11).It will be interesting to see whether these new insights on DNA methylation and disease-specific gene expression changes can be further developed into novel diagnostic epigenetic markers, to see how they will contribute to unraveling disease mechanisms, and to assess their therapeutic implications.
The combination of the HER2 antibody trastuzumab, the EGFR tyrosine kinase inhibitor gefitinib, and docetaxel as first-line therapy in patients with HER2 overexpressing stage IV breast carcinoma
Authors: G. Somlo, M. Koczywas, T. Luu, M. McNamara, V. Bedell, M. L. Slovak, S. Wilczynski, R. Morgan, C. Russell, P. Frankel
Journal: Journal of Clinical Oncology (2007)

1057 Background: Interference with both HER2 and epidermal growth factor (EGFR) dependent pathways may improve therapeutic efficacy of docetaxel (doc) in pts with HER2 overexpressing (+) BC. Methods: Patients (pts) without prior chemotherapy (Rx) exposure for stage IV HER-2 + BC were enrolled. Prior hormonal or adjuvant Rx inclusive of taxane or trastuzumab (tras) were allowed. A left ventricular ejection fraction of &gt; 45% and ECOG performance status of ≥ 2 were required. Pts were to receive doc 75 m 2 , tras every 3 weeks, and gefitinib (gef) 250 mg daily. BC samples from 12 pts were analyzed by FISH for HER2 and EGFR amplification (amp), and topoisomerase II (topo II) amp or loss. IHC was to be performed to examine p-Src, p-STAT3, Ki67 and survivin expression. Results: The median age was 49 (range, 34–67) and ECOG performance status 0.5 (0–1). The first 9 patients received gef 250 mg daily; 2 pts received dox 75 mg/m 2 and developed grade 3 febrile neutropenia (neu), hence, additional pts received doc at 60 mg/m 2 : 3 more episodes of grade 3 neu were seen. Gef was held due to grade 3 dermatitis (2 pts) and diarrhea (2 pts). Pts received a median of 6 cycles (3–10). Gef schedule then was changed, and was prescribed on days 2–14, only. Three of the next 9 pts experienced grades 3 or 4 neu, and we observed 3 cases of grade 3 gastrointestinal toxicities; pts were able to receive 11 + (range; 5–25+) cycles on this schedule (p&lt;0.04). There were 4 complete (CR)and 6 partial R (23 % CR, 59 % overall R), and 3 pts had stable disease (SD; all R and SD confirmed); 3 pts progressed at 4, 4, and 5 mos, 1 pt was inevaluable. The median time to progression is 12 + mos. Samples from 3 pts revealed topo II amplification and one pt sample showed loss of one topo II allele; none were amplified for EGFR. Outcome will be correlated with IHC defined signal trasduction status and proliferation rates. Conclusions: The combination of doc, tras, and short course of gef is feasible, with encouraging R and SD rates and time to progression. Further exploration of simultaneous blockage of multiple signal transduction pathways is indicated in combination with chemoRx. Supported by NCI CA33572 and by a grant from AstraZeneca. No significant financial relationships to disclose.
Selective Killing of Oncogenic Human Cells Cocultivated With Normal Human Fibroblasts2
Authors: Robert C. Warrington
Journal: JNCI Journal of the National Cancer Institute (1978)

Journal Article Selective Killing of Oncogenic Human Cells Cocultivated With Normal Human Fibroblasts Get access Robert C. Warrington Robert C. Warrington 4 3Microbiology Section, University of Connecticut, Storrs, Conn. 06268. 4Address reprint requests to Dr. Warrington at his present address: Department of Cancer Research, University of Saskatchewan, Saskatoon, Saskatchewan S7N OWO, Canada. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 61, Issue 1, July 1978, Pages 69–73, https://doi.org/10.1093/jnci/61.1.69 Published: 01 July 1978 Article history Received: 01 November 1977 Accepted: 01 February 1978 Published: 01 July 1978
Cost-effectiveness (CE) of lapatinib plus capecitabine (L+C) in women with HER2+ metastatic breast cancer (MBC) who received prior therapy with trastuzumab (TZ) based on updated survival data from EGF100151
Authors: T. DeLea, P. Tappenden, O. Sofrygin, J. Karnon, M. Amonkar, D. Browning, H. J. Rudge, M. D. Walker
Journal: Journal of Clinical Oncology (2008)

6559 Background: Lapatinib, an oral small molecule dual tyrosine kinase inhibitor binds intracellularly to the ATP site of the EGFR and HER2 receptors. In EGF100151, L+C improved time to progression (TTP) and progression free survival (PFS) vs capecitabine alone (C- only) in women with HER2+ MBC who received prior therapy with TZ. Methods: We evaluated the CE (ΔCosts/ΔQuality Adjusted Life Years [QALYs]) of L+C vs C-only in women with HER2+ MBC who have received prior therapy with TZ from the UK NHS (National Health Service) perspective using an assumed acquisition cost and updated survival data (March 2007 EGF100151 data-cutoff). Because many patients in clinical practice receive monotherapy with vinorelbine (V-only) or TZ-only or combination therapy with TZ and C (TZ+C) or TZ and V (TZ+V), we also assessed the CE of L+C vs these treatment strategies. PFS and overall survival (OS) with L+C and C-only were based on Weibull survival functions estimated from data in EGF100151. Post-progression survival (PPS) for L+C and C-only were calculated as OS minus PFS. Since data from comparative trials in this population are lacking, PFS with TZ+C, TZ+V and TZ-only were estimated from published cohort studies of continued TZ±chemotherapy (TZ±CT) following progression; PPS was assumed to equal that of L+C. PFS and OS with V-only were assumed equal to that of C-only. Drug costs were from the British National Formulary; other costs were from NHS reference costs and published studies. Utility values for PFS were from EQ-5D data in EGF100151; for PPS, from a UK community-based preference study in MBC. Costs and QALYs were discounted at 3.5% annually. Results: L+C is dominant (provides more QALYs at a lower cost) vs TZ+V, TZ+C, and TZ-only. Conclusions: Using updated survival data from EGF100151 and indirect comparisons in the absence of head-to-head data, suggests that L+C is a cost effective therapy vs TZ±CT from the UK NHS perspective. L+C C-only V- only TZ+V TZ+C TZ-only Total costs (£) 26,489 12,745 15,034 30,997 28,906 27,619 Total QALYs 0.901 0.738 0.738 0.762 0.762 0.762 CE L+C vs (£/QALY) 83,999 70,011 dominant dominant dominant Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline
Stage III neuroblastoma over 1 year of age at diagnosis: improved survival with intensive multimodality therapy including multiple alkylating agents.
Authors: D C West, R C Shamberger, R M Macklis, H P Kozakewich, A S Wayne, S G Kreissman, B R Korf, B Lavally, H E Grier
Journal: Journal of Clinical Oncology (1993)

PURPOSE A nonrandomized, single-arm trial was conducted to assess the efficacy of multimodality therapy including intensive chemotherapy with multiple alkylating agents in the treatment of children with Evans stage III neuroblastoma older than 1 year at diagnosis. PATIENTS AND METHODS Twenty-five patients with a median age of 18 months at diagnosis were treated with multimodality therapy including surgery and chemotherapy using either nitrogen mustard (mechlorethamine), doxorubicin, cisplatin, dacarbazine (DTIC), vincristine, and cyclophosphamide (MADDOC) or cisplatin and cyclophosphamide induction followed by maintenance MADDOC (induction MADDOC) protocols. Sixteen of 25 patients also received radiotherapy to the tumor bed and primary lymph nodes. Event-free survival (EFS) was compared with that reported previously in the literature. N-myc amplification was evaluated prospectively and the Shimada classification was evaluated retrospectively as potential prognostic factors. RESULTS We report a 72% EFS (95% confidence interval +/- 18%) with a median follow-up of 85 months. EFS was significantly worse for patients with tumors demonstrating N-myc amplification (P = .018). Patients classified as favorable according to the Shimada system experienced a significantly better EFS (P = .04), but unfavorable patients still maintained a 60% EFS. CONCLUSION Intensive multimodality treatment including MADDOC and induction MADDOC chemotherapy provides a very good EFS for children older than 1 year who have stage III neuroblastoma. Children classified as favorable according to the Shimada system have a better prognosis. Patients whose tumors demonstrate N-myc amplification have a poor prognosis despite therapy.
Mortality Associated With Mode of Presentation in the Acquired Immune Deficiency Syndrome&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Andrew R. Moss, Ph.D.
 4, Gerald McCallum, M.D., Paul A. Volberding, M.D., Peter Bacchetti, M.S., Selma Dritz, M.D.
Journal: JNCI Journal of the National Cancer Institute (1984)

A population-based survival study was done for all cases of the acquired immune deficiency syndrome diagnosed in the city of San Francisco through May 1983. Follow-up was obtained for 165 of 173 diagnosed cases. Median survival among 75 patients presenting with Kaposi's sarcoma (KS) alone was 21 months. Median survival among 90 patients presenting with opportunistic infections, primarily Pneumocystis carlnii pneumonia, was 9 months; survival at 21 months was zero. Survival among patients presenting with both KS and opportunistic infections was not statistically different from survival among patients presenting with opportunistic infections only. When cases were divided into those diagnosed before and after May 1982, there was no significant improvement in survival from diagnosis in the more recently diagnosed cohort.
Clinical Outcome Determinants for Sequentially Transformed Indolent Lymphomas Treated with or without Autologous Stem Cell Transplantation
Authors: Charlotte Madsen, Martin Bjerregaard Pedersen, Maja Ølholm Vase, Erik Segel, Knud Bendix, Bo Amdi Jensen, Paw Jensen, Michael Boe Moeller, Preben Johansen, Lars Munksgaard, Peter de Nully Brown, Francesco d'Amore
Journal: Blood (2014)
Occurrence and Transplantation of Carcinogen-Induced Hyperplastic Nodules in Fischer Rats&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Leonard J. Beuving, Howard A. Bern, Kenneth B. DeOme
Journal: JNCI Journal of the National Cancer Institute (1967)

Female inbred Fischer rats, age 50–60 days, were given 10, 15, or 20 mg 7,12-dimethylbenz[a]anthracene (DMBA) in sesame oil in a single dose by gastric intubation. Mammary gland tumors or hyperplastic nodules, or both, were found in all treated animals, whereas none was observed in the sesame oil-treated controls. Nodules appeared with about equal frequency in all dose groups. However, the number of lesions in all groups increased with time after carcinogen administration. Similar lesions were seen in the mammary glands of old male and multiparous female rats. The hyperplastic structures observed in the mammary glands of DMBA-treated female rats were placed into four categories by morphologic criteria derived from stained wholemounts and histologic sections: hyperplastic alveolar nodules, distended alveolar nodules, fibrous nodules, and ductal hyperplasias. Eighty hyperplastic alveolar nodules were seen in the mammary glands of anesthetized animals by intraductal injection of the animal's blood. These nodules were transplanted into the abdominal gland-free mammary fat pads of 3-week-old female rats. No tumors developed in the hyperplastic outgrowths of the transplanted nodules. Outgrowths showed a variety of patterns. OF the carcinogen-treated normal tissues placed in the contralateral fat pads, none produced hyperplastic outgrowths as such, although 9% showed hyperplastic nodules in the otherwise normal outgrowths. It is apparent that both a variety of hyperplastic lesions and tumors result from the action of DMBA on rat mammary glands. Although the hyperplastic alveolar lesions give rise to hyperplastic outgrowths on transplantation, no tumors have yet been observed from such transplants within the test period. Thus these lesions in the rat must not yet be defined as preneoplastic.
Abstract 5261: Platelet-Depletion Ameliorates Cardiac Function and Disease Severity in Experimental Autoimmune Myocarditis
Authors: Martin Russ, Barbara Seliger, Steffen Hauptmann, Rene Marty, Jürgen Bukur, Urs Eriksson, Sebastian Schubert, Karl Werdan, Michael Buerke
Journal: Circulation (2008)

Introduction: Experimental Autoimmune Myocarditis (EAM) is a CD4+ T cell mediated model of inflammatory cardiomyopathy. Activated platelets express CD154, a molecule critical to adaptive immune responses, which has been implicated in platelet-mediated modulation of inflammation. Hypothesis: Platelets are critical for the generation of heart-specific, autoreactive T-cell responses in a model of experimental Autoimmune Myocarditis. Methods: BALB/c mice were immunized twice at day 0 and day 7 with 100μg alpha-MyHC-peptide (614–29) together with Complete Freund‘s adjuvant. Platelets were markedly depleted by i.v. injection of a GP1alpha antibody every 5th day (n=8). Control mice were injected with a non-depleting isotype antibody (n=8). Mice were assessed at day 28 for heart dimensions and cardiac function using echocardiography. After lethal anesthesia, hearts were removed and analyzed for heart weight/body weight ratio and histological severity scores. CD4+ T-cells were isolated from spleens, and analyzed for CD154 and IL-17 expression using FACS after in vitro re-stimulation on alpha-MyHC pulsed, irradiated antigen presenting cells. Results: Modest platelet depletion protected from left ventricular dilatation, and preserved left ventricular ejection fraction in immunized mice. Myocarditis prevalence and severity scores were significantly reduced in depleted animals. Relative numbers of spleen-derived CD4+ T-cells expressing CD154 or IL-17, were significantly reduced in the treatment group (table ). Conclusion: Our findings suggest that platelets might play a critical role in the development of heart-specific autoimmunity and cardiomyopathy. Further studies are needed to confirm these findings, which suggest a novel treatment approach for inflammatory cardiomyopathy. Echocardiography - Histology - FACS